Phentermine - Citius Pharmaceuticals

Drug Profile

Phentermine - Citius Pharmaceuticals

Alternative Names: Phentermine hydrochloride; Suprenza

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alpex Pharma
  • Developer Citius Pharmaceuticals Inc
  • Class Amphetamines; Anorectics; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Obesity

Most Recent Events

  • 01 Jul 2016 Withdrawn for Obesity (Adjunctive treatment) in USA (PO)
  • 18 Sep 2014 Citius Pharmaceuticals plans additional phase II trial for Obesity in USA (PO) (Citius Pharmaceuticals, Form 8-K filed in September 2014)
  • 01 Apr 2012 Launched for Obesity (Adjunctive treatment, With exercise, behavioural modification and caloric restriction) in USA (PO, 15mg, 30mg)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top